Normal
Seems to be a buy candidate on fundamentals but still risky as a chart buy. Guessing the price decline has reflected a sustained disappointment with the H1 result announced in Feb. Revenue was up but costs also up on a few lines: cost of sales, general admin, depreciation/amortisation - resulting in a significant looking drop in NPAT margin compared to previous 4 half years.Hope to be disciplined enough to keep a close eye on chart development as this might be another galumay special (like SXE)Not HeldWEEKLY[ATTACH=full]175569[/ATTACH][ATTACH=full]175570[/ATTACH]
Seems to be a buy candidate on fundamentals but still risky as a chart buy. Guessing the price decline has reflected a sustained disappointment with the H1 result announced in Feb. Revenue was up but costs also up on a few lines: cost of sales, general admin, depreciation/amortisation - resulting in a significant looking drop in NPAT margin compared to previous 4 half years.
Hope to be disciplined enough to keep a close eye on chart development as this might be another galumay special (like SXE)
Not Held
WEEKLY
[ATTACH=full]175569[/ATTACH]
[ATTACH=full]175570[/ATTACH]
Hello and welcome to Aussie Stock Forums!
To gain full access you must register. Registration is free and takes only a few seconds to complete.
Already a member? Log in here.
